Merus N.V. Stock News

MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rat...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a p...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.